TG Therapeutics (TGTX) is a biopharmaceutical company excelling in treatments for B-cell mediated diseases, with a promising flagship product, Briumvi, targeting Multiple Sclerosis. The company's financial growth potential and strategic agreements position it for success in the competitive market.